Literature DB >> 11762207

Animal models of schizophrenia: a critical review.

E R Marcotte1, D M Pearson, L K Srivastava.   

Abstract

Current research into schizophrenia has remained highly fragmented, much like the clinical presentation of the disease itself. Differing theories as to the cause and progression of schizophrenia, as well as the heterogeneity of clinical symptoms, have made it difficult to develop a coherent framework suitable for animal modelling. However, a number of limited animal models have been developed to explore various causative theories and to test specific mechanistic hypotheses. Historically, these models have been based on the manipulation of neurotransmitter systems believed to be involved in schizophrenia. In recent years, the emphasis has shifted to targeting relevant brain regions in an attempt to explore potential etiologic hypotheses. The specific animal models developed within these frameworks are described in this review. Emphasis is placed on the critical evaluation of currently available models because these models help to shape the direction of future research.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11762207      PMCID: PMC167198     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  261 in total

1.  Enhanced nucleus accumbens dopamine and plasma corticosterone stress responses in adult rats with neonatal excitotoxic lesions to the medial prefrontal cortex.

Authors:  W G Brake; G Flores; D Francis; M J Meaney; L K Srivastava; A Gratton
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

Review 2.  Gating of information flow within the limbic system and the pathophysiology of schizophrenia.

Authors:  A A Grace
Journal:  Brain Res Brain Res Rev       Date:  2000-03

3.  Implications of normal brain development for the pathogenesis of schizophrenia.

Authors:  D R Weinberger
Journal:  Arch Gen Psychiatry       Date:  1987-07

Review 4.  Serotonin model of schizophrenia: emerging role of glutamate mechanisms.

Authors:  G K Aghajanian; G J Marek
Journal:  Brain Res Brain Res Rev       Date:  2000-03

Review 5.  Toxicity of drug abuse--amphetamine designer drugs (ecstasy): mental effects and consequences of single dose use.

Authors:  J Mørland
Journal:  Toxicol Lett       Date:  2000-03-15       Impact factor: 4.372

6.  Semaphorin 3A is a chemoattractant for cortical apical dendrites.

Authors:  F Polleux; T Morrow; A Ghosh
Journal:  Nature       Date:  2000-04-06       Impact factor: 49.962

7.  A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis.

Authors:  T Sharp; T Zetterström; T Ljungberg; U Ungerstedt
Journal:  Brain Res       Date:  1987-01-20       Impact factor: 3.252

8.  Provocative tests with psychostimulant drugs in schizophrenia.

Authors:  J A Lieberman; J M Kane; J Alvir
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

9.  Left globus pallidus abnormality in never-medicated patients with schizophrenia.

Authors:  T S Early; E M Reiman; M E Raichle; E L Spitznagel
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

10.  Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.

Authors:  D F Wong; H N Wagner; L E Tune; R F Dannals; G D Pearlson; J M Links; C A Tamminga; E P Broussolle; H T Ravert; A A Wilson; J K Toung; J Malat; J A Williams; L A O'Tuama; S H Snyder; M J Kuhar; A Gjedde
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

View more
  33 in total

1.  Chronic administration of the neurotrophic agent cerebrolysin ameliorates the behavioral and morphological changes induced by neonatal ventral hippocampus lesion in a rat model of schizophrenia.

Authors:  Rubén Antonio Vázquez-Roque; Brenda Ramos; Carolina Tecuatl; Ismael Juárez; Anthony Adame; Fidel de la Cruz; Sergio Zamudio; Raúl Mena; Edward Rockenstein; Eliezer Masliah; Gonzalo Flores
Journal:  J Neurosci Res       Date:  2011-09-19       Impact factor: 4.164

Review 2.  Semantics and N400: insights for schizophrenia.

Authors:  Namita Kumar; J Bruno Debruille
Journal:  J Psychiatry Neurosci       Date:  2004-03       Impact factor: 6.186

3.  Loss of function studies in mice and genetic association link receptor protein tyrosine phosphatase α to schizophrenia.

Authors:  Nagahide Takahashi; Karin Sandager Nielsen; Branko Aleksic; Steffen Petersen; Masashi Ikeda; Itaru Kushima; Nathalie Vacaresse; Hiroshi Ujike; Nakao Iwata; Véronique Dubreuil; Naheed Mirza; Takeshi Sakurai; Norio Ozaki; Joseph D Buxbaum; Jan Sap
Journal:  Biol Psychiatry       Date:  2011-08-10       Impact factor: 13.382

Review 4.  Proteomics of the human brain: sub-proteomes might hold the key to handle brain complexity.

Authors:  F Tribl; K Marcus; G Bringmann; H E Meyer; M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  2006-07-13       Impact factor: 3.575

5.  Neonatal exposure to phenobarbital potentiates schizophrenia-like behavioral outcomes in the rat.

Authors:  S K Bhardwaj; P A Forcelli; G Palchik; K Gale; L K Srivastava; A Kondratyev
Journal:  Neuropharmacology       Date:  2012-02-15       Impact factor: 5.250

6.  Antipsychotic-like effects of a neurotensin receptor type 1 agonist.

Authors:  Chelsea A Vadnie; Jennifer Ayers-Ringler; Alfredo Oliveros; Osama A Abulseoud; Sun Choi; Mario J Hitschfeld; Doo-Sup Choi
Journal:  Behav Brain Res       Date:  2016-02-22       Impact factor: 3.332

7.  The nicotine metabolite, cotinine, attenuates glutamate (NMDA) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in rats.

Authors:  Alvin V Terry; Jerry J Buccafusco; R Foster Schade; Leah Vandenhuerk; Patrick M Callahan; Wayne D Beck; Elizabeth J Hutchings; James M Chapman; Pei Li; Michael G Bartlett
Journal:  Biochem Pharmacol       Date:  2012-01-08       Impact factor: 5.858

8.  Infusions of Nerve Growth Factor Into the Developing Frontal Cortex Leads to Deficits in Behavioral Flexibility and Increased Perseverance.

Authors:  Sagar J Desai; Brian L Allman; Nagalingam Rajakumar
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

9.  Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats.

Authors:  Maria Sabrina Spano; Liana Fattore; Francesca Cadeddu; Walter Fratta; Paola Fadda
Journal:  Psychopharmacology (Berl)       Date:  2012-08-19       Impact factor: 4.530

10.  Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia.

Authors:  Li-Jin Chew; Paolo Fusar-Poli; Thomas Schmitz
Journal:  Dev Neurosci       Date:  2013-02-27       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.